Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma

被引：0
|
作者：
Liu, Jiajian
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2663
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Serum Concentrations of TIM-3, LAG-3, and PD-1 in Patients with Hemorrhagic Fever with Renal Syndrome
    Safranko, Zeljka Macak
    Jakopec, Lana
    Svagusa, Karla
    Krajinovic, Lidija Cvetko
    Tomasovic, Domagoj
    Lukic, Ljiljana
    Markotic, Alemka
    LIFE-BASEL, 2024, 14 (05):
  • [32] Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1
    Herrera-Camacho, Irma
    Anaya-Ruiz, Maricruz
    Perez-Santos, Martin
    Millan-Perez Pena, Lourdes
    Bandala, Cindy
    Landeta, Gerardo
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2019, 29 (08) : 587 - 593
  • [33] EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Price, Timothy
    Chawla, Sant
    Falchook, Gerald
    Prenen, Hans
    Lugowska, Iwona
    Subbiah, Vivek
    Monzon, Jose
    Ozawa, Yuichi
    Arkenau, Tobias
    Lima, Caio Rocha
    Kuboki, Yasutoshi
    Nishina, Tomohiro
    Hui, Mun
    Rasmussen, Erik
    Wong, Hansen
    Najmi, Saltanat
    Sadraei, Nooshin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A245 - A245
  • [34] A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)
    Shu, Pei
    Li, Xiaoyu
    Yuan, Li
    Xie, Hui
    Zhou, Qi
    Wang, Yongsheng
    Li, Qiu
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
    Keam, Bhumsuk
    Kim, Tae Min
    Oh, Do-Youn
    Ock, Chan-Young
    Kang, Won Ki
    Park, Yeon Hee
    Lee, Jeeyun
    Lee, Ji Hye
    Song, Yun Jeong
    Park, Young Suk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
    Xiong, Jianping
    Ouyang, Weiwei
    Yang, Mengxiang
    Gao, Zhenyuan
    Zhou, Huan
    Lou, Hanmei
    Guo, Yabing
    Xu, Zhongyuan
    Zheng, Ling
    Liu, Ying
    Wang, Zhongfeng
    Sun, Ping
    Niyazi, Huerxidan
    Wang, Jianhua
    Chen, Yan
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    Guo, Weijian
    ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
  • [39] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
    Marcq, Elly
    De Waele, Jorrit
    Van Audenaerde, Jonas
    Lion, Eva
    Santermans, Eva
    Hens, Niel
    Pauwels, Patrick
    van Meerbeeck, Jan P.
    Smits, Evelien L. J.
    ONCOTARGET, 2017, 8 (52) : 89722 - 89735
12345